Prelude Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Prelude Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-278,465	Closed	-$16.7M	–	2313
2019 Q4	$16.7M	Buy	+278,465	New	+$10.5M	0.63%	13
2018 Q2	–	Sell	-7,022	Closed	-$211K	–	2081
2018 Q1	$211K	Sell	7,022 -9,537	-58%	-$323K	0.02%	670
2017 Q4	$517K	Buy	16,559 +6,379	+63%	+$175K	0.04%	420
2017 Q3	$285K	Buy	+10,180	New	+$221K	0.03%	530

Prelude Capital Management's BOLD Position: Q1 2020 in Review

Prelude Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 278,465 shares — an estimated $16.7M sold.

Prelude Capital Management first reported a position in BOLD in Q3 2017 and held it in 4 quarters. The position peaked at $16.7M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Prelude Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Prelude Capital Management sold 278,465 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $16.7M.
Prelude Capital Management first reported a position in Audentes Therapeutics, Inc in Q3 2017 and held it in 4 quarters.
Prelude Capital Management's Audentes Therapeutics, Inc position peaked at $16.7M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.